Equities

ICON PLC

ICON PLC

Actions
Health CareMedical Equipment and Services
  • Price (USD)214.93
  • Today's Change-0.08 / -0.04%
  • Shares traded2.21m
  • 1 Year change-16.69%
  • Beta1.2185
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

  • Revenue in USD (TTM)8.31bn
  • Net income in USD747.89m
  • Incorporated1989
  • Employees42.25k
  • Location
    ICON PLCSouth County Business ParkLEOPARDSTOWN, Dublin 18DUBLIN 00000IrelandIRL
  • Phone+353 12912000
  • Fax+353 12912700
  • Websitehttps://www.iconplc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revolution Medicines Inc742.00k-567.06m10.17bn490.00--6.47--13,702.40-3.59-3.590.00479.340.0005--4.801,962.96-41.28-29.76-44.46-32.59-----76,423.31-606.93----0.00---67.27-10.50-75.46--38.82--
Exelixis Inc2.08bn466.92m10.35bn1.31k23.104.5520.934.971.571.576.927.960.70123.398.041,589,006.0015.738.8618.089.9196.2596.3022.4315.433.88--0.000.0013.6016.4713.98-21.343.98--
Charles River Lbrtrs ntrntl Inc4.06bn413.08m11.01bn20.00k26.892.9114.342.718.018.0178.6373.970.52038.275.23203,045.805.486.466.337.6235.9336.9910.5411.581.144.960.37840.003.8612.75-2.3916.6917.86--
Medpace Holdings Inc2.07bn365.57m11.28bn5.90k31.7712.7628.595.4511.4211.4264.7028.421.16--6.85350,994.3020.4813.9443.5123.1829.6928.8417.6615.23----0.00--29.1721.7615.2631.1717.99--
Tempus AI Inc640.44m-800.71m11.38bn2.30k--213.26--17.78-8.29-8.294.440.3459----------------53.18---116.06--2.55-14.950.891--65.85--20.35------
Sarepta Therapeutics Inc1.64bn121.85m11.62bn1.31k100.009.5172.387.081.221.2216.3012.790.4890.57034.351,248,362.003.63-21.634.38-25.7585.9286.657.43-77.053.03--0.5013--33.2632.8023.81--6.30--
BIO-TECHNE Corp1.17bn150.68m12.07bn3.10k80.805.6446.0610.300.94020.94027.2913.460.42672.155.47377,930.005.499.425.7710.0465.9367.2912.8621.413.2618.070.12322.791.9710.17-41.0711.8619.870.00
Neurocrine Biosciences, Inc.2.24bn385.90m12.73bn1.70k33.674.6830.935.683.733.7321.6726.870.70270.89014.991,602,000.0012.099.7714.6712.1998.5298.5117.2114.794.2610.280.00--26.7633.1361.6263.902.67--
Insmed Inc342.96m-864.29m13.16bn912.00--27.21--38.36-5.56-5.562.212.700.20310.88488.81376,050.40-51.17-40.96-59.16-46.8877.2577.99-252.01-212.925.99-18.410.6702--24.3998.78-55.66---2.15--
Vaxcyte Inc0.00-507.65m13.29bn254.00--3.88-----4.55-4.550.0027.470.00----0.00-20.08-34.22-20.95-37.21------------0.00-------80.00--107.28--
Summit Therapeutics Inc0.00-196.68m15.79bn105.00--36.04-----0.2768-0.27680.000.59410.00----0.00-54.53-77.32-71.71-86.35-------20,989.46----0.053---100.00---680.54---4.84--
ICON PLC8.31bn747.89m17.74bn42.25k23.901.8213.762.148.998.9999.87118.390.4852--2.99202,112.504.373.935.244.8029.6328.919.007.37--4.410.2599--4.8925.6221.1813.6723.79--
Moderna Inc5.08bn-2.22bn18.00bn5.60k--1.51--3.54-5.81-5.8113.1430.980.28832.442.96907,321.40-12.6220.95-15.5229.5178.43---43.7732.104.20--0.05210.00-64.45119.28-156.37--46.22--
United Therapeutics Corporation2.76bn1.11bn18.30bn1.17k18.023.0015.556.6422.7522.7556.36136.740.38972.439.182,359,760.0015.7110.3817.7311.2788.9491.4740.3129.254.41--0.06150.0020.207.4135.4010.894.55--
Data as of Nov 08 2024. Currency figures normalised to ICON PLC's reporting currency: US Dollar USD

Institutional shareholders

35.46%Per cent of shares held by top holders
HolderShares% Held
WCM Investment Management LLCas of 30 Sep 20246.65m8.04%
Massachusetts Financial Services Co.as of 30 Jun 20245.00m6.04%
Ninety One UK Ltd.as of 30 Jun 20242.68m3.23%
Boston Partners Global Investors, Inc.as of 30 Jun 20242.62m3.16%
T. Rowe Price Associates, Inc. (IM)as of 30 Jun 20242.62m3.16%
Lazard Asset Management LLCas of 30 Jun 20242.45m2.96%
Wellington Management Co. LLPas of 30 Jun 20242.17m2.63%
Capital Research & Management Co. (Global Investors)as of 30 Jun 20241.90m2.29%
Fidelity Management & Research Co. LLCas of 30 Jun 20241.76m2.13%
ClearBridge Investments LLCas of 30 Jun 20241.51m1.82%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.